Navigation Links
Kristalose(R) Offers Prescription Alternative to MiraLAX(R) and Other PEG 3350 Products

Unique, crystalline laxative designed to enhance patient acceptance and


NASHVILLE, Tenn., Feb. 26 /PRNewswire/ -- Kristalose(R), a prescription laxative product that treats acute and chronic constipation, may be an effective option for physicians and pharmacists looking for a prescription alternative to MiraLAX(R) and generic PEG 3350 products. Marketed in the U.S. by Cumberland Pharmaceuticals, Kristalose(R) is now the only prescription- strength laxative available in a convenient powder packet.

(Photo: )

Previously available by prescription, MiraLAX(R) (polyethylene glycol 3350 or PEG 3350) became an over-the-counter (OTC) treatment for occasional constipation in early 2007. Due to U.S. Food and Drug Administration policy which does not allow the same formulation of a product to be marketed simultaneously as both a prescription and OTC drug, generic PEG 3350 products are now also becoming unavailable by prescription.(1) These generic products will not be available on the OTC market for at least three years following the MiraLAX(R) introduction due to marketing exclusivity granted by the FDA.

Physicians wrote more than 9 million prescriptions for MiraLAX(R) and generic PEG 3350 products in 2006 for treatment of constipation. As the PEG 3350 products are becoming unavailable by prescription, Cumberland believes Kristalose(R) offers a safe, effective alternative for physicians looking to retain prescriptive control for their patients.

Kristalose(R) (lactulose) for Oral Solution is a proprietary prescription laxative and the brand name for a unique crystalline form of lactulose that treats acute and chronic constipation. Available in pre-dosed packets, the drug dissolves quickly in four ounces of water, offering patients a virtually tasteless and grit-free alternative to other liquid lactulose treatments. There are no age limitations or length of use restrictions for Kristalose(R), and it is the only osmotic prescription laxative still sampled to physicians.

"Kristalose(R) has a long history of providing safe and effective relief to sufferers of acute and chronic constipation with few side effects," said A.J. Kazimi, CEO of Cumberland Pharmaceuticals. "We look forward to communicating the unique features of this drug to the medical community and ultimately to patients who may benefit from it."

Cumberland Pharmaceuticals Inc. is a Tennessee-based specialty pharmaceutical company that develops and markets niche pharmaceutical products for specific physician segments including critical care, emergency medicine and gastroenterology. Cumberland is dedicated to providing high-quality products which fill unmet medical needs. For more information, please visit the Cumberland Pharmaceuticals website at or

To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and actual results or events may differ from Cumberland's expectations. Results may differ depending upon, among other things, the impact of actions by regulatory authorities on the marketing and distribution of products that compete with Kristalose(R). These statements speak only as of the date of this press release, and Cumberland undertakes no obligation to update or revise the statements.

Kristalose(R) is indicated for the treatment of acute and chronic constipation. It is a unique, proprietary, crystalline form of lactulose, with no restrictions on length of therapy or patient age. Initial dosing may produce flatulence and intestinal cramps, which are usually transient. Excessive dosage can lead to diarrhea with potential complications such as loss of fluids, hypokalemia and hypernatremia. Nausea and vomiting have been reported. Use with caution in diabetics. Kristalose(R) is contraindicated in patients who require a low-galactose diet. Elderly, debilitated patients who receive lactulose for more than six months should have serum electrolytes (potassium, chloride, carbon dioxide) measured periodically.


(1) Food and Drug Administration 21 CFR Part 310. Drug Approvals:

circumstances under which an active ingredient may be simultaneously

marketed in both a prescription product and an over-the-counter drug

product. Federal Register. Sept. 2005; 70(169) 52050-51. While the

FDA's interpretation does not have the force of law and is subject to

change at any time, it is the current interpretation of the FDA upon

which Cumberland believes it can rely.

SOURCE Cumberland Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Health care incentive model offers collaborative approach
2. Eye-staining technique offers early detection for dry eye syndrome
3. Governor Rendell Offers adultBasic Coverage to 35,000 Uninsured Pennsylvanians
4. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
5. Psoriasis Cure Now offers Back to School Resources for Parents of Children with Psoriasis
6. ADDAS Awareness Campaign Offers Resources and Education to Adults Living with AD/HD and Professionals Working With Them
7. Regence Offers InterM to Fill Gap for the Uninsured
8. National Non-Profit Organization Offers Free Mental Health Services to Military and Military Families
9. Blue Cross Blue Shield of Michigan Offers New Approach to Customer Group Wellness
10. ProAssurance Group Offers Coverage for Community Based Hospitals in Michigan
11. Super Jake Foundation Offers Hope for Pediatric Cancer
Post Your Comments:
(Date:10/13/2017)... ... October 13, 2017 , ... Many families have long-term ... long-term care insurance companies have a waiver for care if the client has a ... when the family pays for care, is often waived, so the benefits from their ...
(Date:10/13/2017)... ... ... Ellevate Network, the leading network for professional women, brought together some of ... their inaugural Summit in New York City in June. The event was livestreamed with ... 3 million. To watch the Mobilize Women video, click here . , ...
(Date:10/13/2017)... ... 13, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House of ... popular and least understood books in the Holy Scriptures, Revelation. The Book of Revelation ... scholars for centuries. Many have tossed it off as mere rubbish, but Yisrayl Hawkins ...
(Date:10/13/2017)... , ... October 13, 2017 , ... ... and Agile Software Development, has been awarded a contract by the Center for ... Agreement (BPA) aims to accelerate the enterprise use of Agile methodologies in a ...
(Date:10/13/2017)... ... October 13, 2017 , ... “America On The Brink”: the ... “America On The Brink” is the creation of published author, William Nowers. Captain ... As a WWII veteran, he spent thirty years in the Navy. Following his ...
Breaking Medicine News(10 mins):
(Date:9/27/2017)... Sept. 27, 2017  Commended for their devotion to personalized ... Ranked as number one in the South Florida Business Journal,s ... Inc. 5000 yearly list, the national specialty pharmacy has found ... Bardisa will soon be honored by SFBJ as the ... Set to receive his award in October, Bardisa ...
(Date:9/25/2017)... 25, 2017   Montrium , an industry ... today—from the IQPC Trial Master Files & Inspection ... that EastHORN Clinical Services has selected eTMF ... TMF management. EastHORN, a leading European contract research ... increase transparency to enable greater collaboration with sponsors, ...
(Date:9/23/2017)... , Sept. 22, 2017 Janssen Biotech, Inc. ... response letter from the U.S. Food and Drug Administration ... of sirukumab for the treatment of moderately to severely ... additional clinical data are needed to further evaluate the ... severely active RA. ...
Breaking Medicine Technology: